drugset / Trial / NCT07120984

A Study to Evaluate the Safety and Efficacy of L19TNF With Alkylating Chemotherapy for Patients With Recurrent IDH-mutant Astrocytoma or Oligodendroglioma

NCT07120984

Phase 2 Not yet recruiting 52 enrolled Philogen S.p.A.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to explore the safety and efficacy of the antibody-cytokine fusion protein L19TNF alone or in combination with alkylating chemotherapy in patients with recurrent IDH mutant glioma.

Timeline

Start
2026-01-30
Primary completion
2029-01-30
Completion
2029-01-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Lomustine Small molecule
Subject Onfekafusp alfa Protein / enzyme biologic 13 ug/kg
Subject Temozolomide Small molecule

Indications